Impact of a pathologist-driven molecular testing protocol on veterans with non-small cell lung cancer. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not ...

Patients treated with immune checkpoint inhibitors had significantly different survival rates based on the test, regardless of PD ligand 1 classification. A blood-based proteomic test can help ...